The HSPB7 Knockout HeLa Polyclonal Cells are a CRISPR/Cas9-edited polyclonal knockout cell population with targeted disruption of HSPB7 in the HeLa background. This heterogeneous pool ensures robust loss-of-function analysis without clonal artifacts, enabling studies of HSPB7’s role in chaperone-mediated cytoprotection and stress responses.
HeLa cells are an immortalized human cervical epithelial line derived from adenocarcinoma, widely used for their robust stress response pathways. Although non-cardiac, HeLa cells retain core heat shock and protein quality control machinery, making them suitable for investigating the molecular chaperone HSPB7. Their adherent growth and reproducibility support diverse experimental setups.
HSPB7 encodes a small heat shock protein acting as a molecular chaperone, preventing protein aggregation and maintaining sarcomeric integrity in cardiomyocytes. It is transcriptionally regulated by GATA4, MEF2C, NFATc3, and HSF1 under mechanical stress, and interacts with HSPB5, HSPB8, and Bag3 to facilitate chaperone-assisted autophagy. Downstream targets include desmin, actin, and titin, key for myofibril organization and cardiac contraction. In HeLa cells, HSPB7 knockout disrupts this network, potentially altering stress resilience via MAPK and calcineurin-NFAT signaling.
This knockout model decouples HSPB7’s generic chaperone functions from muscle-specific physiology, allowing researchers to examine how its loss impacts stress-induced signaling, protein aggregation, and compensatory regulation of related small heat shock proteins. It provides a valuable system for identifying HSPB7-dependent pathways relevant to dilated cardiomyopathy and heart failure.
Applications include Western blotting for HSPB7 and partners (e.g., HSPB5, Bag3), RT-qPCR for transcriptional changes, immunofluorescence for localization, and stress response assays with heat shock or oxidative stress. Co-immunoprecipitation can map disrupted chaperone complexes, and the model supports drug screening for cardiomyopathy. For further information, contact Ascent Research.
